(Reuters) - Merck & Co Inc reported quarterly sales that were slightly lower than expected, hurt by competition from cheaper generic medicines, and predicted full-year earnings at the lower end of analysts' expectations.
The second-biggest U.S. drugmaker said on Wednesday it earned $781 million, or 26 cents per share, in the fourth quarter. That compared with $908 million, or 30 cents per share, in the year-earlier period.
Revenue fell 4 percent to $11.32 billion. Wall Street was expecting $11.36 billion, according to Thomson Reuters I/B/E/S.
MERCK (MRK.NY)predicted full-year earnings, excluding special items, of $3.35 to $3.53 per share. The average analyst estimate was $3.48 per share.
Separately, Merck said it plans to test its closely followed immuno-oncology drug MK-3475 in combination with medicines being developed by rival drugmakers Pfizer Inc
(Reporting by Ransdell Pierson; Editing by Jeffrey Benkoe and Bernadette Baum)
Relacionados
- Rosell avala que las regiones despobladas españolas accedan a los fondos comunitarios
- Monago valora las obras del Fuerte de San Cristóbal de Badajoz como modelo de "buena utilización" de fondos comunitarios
- El jueves termina el plazo para que los 2 millones de residentes comunitarios se registren para votar en europeas
- El jueves termina el plazo para que los 2 millones de residentes comunitarios se registren para votar en las europeas
- La mujer que lanzó una navaja a su hija tendrá que realizar 75 días de trabajos comunitarios
